Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hyperuricemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44294   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Hyperuricemia. Displaying page 1 of 1.
    EudraCT Number: 2014-003989-24 Sponsor Protocol Number: L_9436 Start Date*: 2014-12-19
    Sponsor Name:Sanofi
    Full Title: Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome
    Medical condition: Hyperuricemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10020907 Hyperuricemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-003176-14 Sponsor Protocol Number: LPS15679 Start Date*: 2021-06-29
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: An Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients with Non-Hodgkin...
    Medical condition: Hyperuricemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020907 Hyperuricemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001858-25 Sponsor Protocol Number: MEIN/11/FEB-GOU/001 Start Date*: 2013-01-28
    Sponsor Name:MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.
    Full Title: A multicentre, randomised, double-blind, parallel group study on the therapeutic efficacy and safety of Febuxostat (taken once daily) and the therapeutic efficacy and safety of Allopurinol on serum...
    Medical condition: hyperuricemia and gout
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    14.1 10027433 - Metabolism and nutrition disorders 10020907 Hyperuricemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-002662-12 Sponsor Protocol Number: PSY102 Start Date*: 2012-12-12
    Sponsor Name:Psyadon Pharmaceuticals Inc.
    Full Title: An Outpatient Phase 3 Efficacy Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects with Lesch-Nyhan Disease (LND).
    Medical condition: Self-injurious behavior in subjects with Lesch-Nyhan Disease (LND).
    Disease: Version SOC Term Classification Code Term Level
    15.0 10010331 - Congenital, familial and genetic disorders 10024245 Lesch-Nyhan syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-006994-10 Sponsor Protocol Number: SEQ-ALO-2007-01 Start Date*: 2009-02-04
    Sponsor Name:Fundación Investigación Biomédica Hospital Príncipe de Asturias
    Full Title: Evaluación de la utilidad del alopurinol en la prevención de la morbimortalidad cardiovascular de los pacientes con enfermedad renal crónica (ERC) e hiperuricemia EVALUATION OF THE USE OF ALLOPURI...
    Medical condition: Enfermedad renal crónica (ERC) e hiperuricemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020907 Hyperuricemia LLT
    9.1 10009119 Chronic renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014762-26 Sponsor Protocol Number: RDEA594-204 Start Date*: 2009-10-27
    Sponsor Name:Ardea Biosciences, Inc.
    Full Title: A Phase 2, Multiple-Dose, Pharmacokinetic and Pharmacodynamic Study of RDEA594 in Gout Patients with Hyperuricemia and Gout with Renal Insufficiency
    Medical condition: Gout.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10018627 Gout LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003573-32 Sponsor Protocol Number: 2022/ABM/01/00027 Start Date*: 2023-12-28
    Sponsor Name:Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
    Full Title: A randomized, double-blind, placebo-controlled study to evaluate the effect of allopurinol on the risk of cardiovascular events in patients at high and very high cardiovascular risk, including the ...
    Medical condition: hyperuricemia, hypertension, ischemic stroke, intracerebral haemorrhage, TIA, heart failure, peripheral arterial disease, atrial fibrillation, diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.1 10027433 - Metabolism and nutrition disorders 10020907 Hyperuricemia LLT
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    22.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    21.1 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    20.0 10007541 - Cardiac disorders 10019279 Heart failure LLT
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    27.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001640-56 Sponsor Protocol Number: PI12/01866 Start Date*: 2014-01-31
    Sponsor Name:Fundación Para la Investigación Biomédica de Córdoba
    Full Title: Crossover clinical trial, randomized, double blind, placebo controlled trial. Modulation of cellular mediators and repair endothelial damage in patients with chronic renal disease through inhibitio...
    Medical condition: Patients with chronic kidney disease and asymptomatic hyperuricemia on the balance of mechanisms of vascular injury and repair.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013055-30 Sponsor Protocol Number: RDEA594-202 Start Date*: 2009-08-30
    Sponsor Name:Ardea Biosciences, Inc.
    Full Title: Randomized, Double-Blind, Multicenter, Placebo-Controlled, Safety and Efficacy Study of RDEA594 Versus Placebo in the Treatment of Hyperuricemia in Patients with Gout “Estudio Multicéntrico, Aleat...
    Medical condition: Gout / Gota
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018627 Gout LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GB (Prematurely Ended) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-005721-82 Sponsor Protocol Number: NL74873.091.20 Start Date*: 2021-02-08
    Sponsor Name:VieCuri
    Full Title: The Gout TrEatment STrategy Project (GO TEST) Overture trial
    Medical condition: gout
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002453-65 Sponsor Protocol Number: ALLO-401 Start Date*: 2012-01-18
    Sponsor Name:Ardea Biosciences, Inc.
    Full Title: Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO)
    Medical condition: Gout
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005567-33 Sponsor Protocol Number: MEIN/14/FEB-PWV/001 Start Date*: 2015-09-11
    Sponsor Name:Menarini International Operations Luxembourg S.A.
    Full Title: The Effect of Intensive Urate Lowering Therapy (ULT) with Febuxostat in Comparison with Allopurinol on Cardiovascular Risk in Patients with Gout Using Surrogate Markers: a Randomized, Controlled Tr...
    Medical condition: Gout
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) PL (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014660-19 Sponsor Protocol Number: RDEA594-203 Start Date*: 2009-12-09
    Sponsor Name:Ardea Biosciences, Inc.
    Full Title: Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Safety, Efficacy and Potential Pharmacokinetic Interaction of RDEA594 and Allopurinol in Gout Patients w...
    Medical condition: Gout
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA